Annovis Bio Inc (ANVS)

Over the past six months, Annovis Bio's stock experienced fluctuations, reaching $2.01 by March 30, 2026, a 34.00% increase from March 31, 2025, with a 52-week range of $1.11 to $5.50. In March 2026, Annovis announced presentations at the AD/PD™ 2026 International Conference and secured DSMB approval to advance its pivotal Phase 3 trial of Buntanetap in Alzheimer's disease and partnered with NeuroRPM for AI-enabled digital biomarker monitoring for its Parkinson's disease clinical trial. In March 2025, the company received a NYSE non-compliance notice due to its market capitalization and stockholders' equity falling below $50 million. In November 2025, Annovis reported progress in its Phase 3 Alzheimer's study and encouraging biomarker results from its Phase 2/3 AD trial. In August 2025, the company focused on enrollment for the pivotal Phase 3 trial in early AD and strengthening global intellectual property protection. In May 2025, Annovis initiated a pivotal Phase 3 clinical trial for Alzheimer's disease with patient enrollment targeting 760 participants.

Annovis Bio, Inc. does not experience demand seasonality. Demand for its potential products depends on the prevalence of diseases like Alzheimer's and Parkinson's, the efficacy and safety of its treatments, and market access, rather than seasonal patterns. The company is focused on clinical trials and regulatory approvals.

Annovis Bio, Inc. is a clinical-stage drug platform company focused on developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. Their lead product candidate, Buntanetap, is in Phase 2/3 trials for Alzheimer's, Phase 3 for Parkinson's, and Phase 2 for Lewy body dementia, targeting neurotoxic proteins. ANVS405, an intravenous version of Buntanetap, is in Phase 2 and 3 clinical trials for acute indications like traumatic brain injury and stroke. ANVS301, an orally administered drug, has completed Phase 1 trials to increase cognitive capability in later stages of AD and dementia.

Annovis Bio, Inc. is headquartered in Malvern, Pennsylvania, United States. Its clinical trials, especially the Phase 3 Alzheimer's study, include clinical sites across the U.S.

Annovis Bio's reputation has been influenced by clinical trial progress and financial updates. Positive developments like DSMB approval for the Phase 3 Alzheimer's trial and encouraging biomarker results have contributed positively. However, the NYSE non-compliance notice in March 2025 negatively affected its reputation, leading to the stock trading with a ".BC" designation.

Annovis Bio, Inc. has 57 institutional owners and shareholders holding 4,267,463 shares, including Vanguard Group Inc. and Marshall Wace, Llp. Institutional Investors own approximately 1.63% to 8.42% of the company's stock, Insiders own 15.22%, and Public Companies and Individual Investors own 76.36%. Michael B. Hoffman owns the most shares.